📋 Tender Overview
First-In-Class Anti-Pvr Mab Ntx1088 - A Novel Oncology Drug That Unlocks The Power Of Human Immune System And Revolutionizes Cancer Care
Nectin Therapeutics (Nectintx) Is A Venture-Backed Company With A Top-Notch Team Focused On Innovative Therapeutic Options For Cancer Patients. To Address The Limitations Of Available Therapies, The Company Has Developed A Diverse Pipeline Of Antibodies That Overcome Immune Inhibitory Pathways Deployed By The Tumours. Ntx1088 Is A Monoclonal Antibody That Binds Human Poliovirus Receptor (Pvr) And Activates Patient’S Immune System To Fight Cancer Through A Triple Mechanism Of Action Never Demonstrated Before. A Comprehensive Preclinical Dataset Was Generated To Show The Robust Antitumor Activity Of Ntx1088 In Vitro And In Vivo. Following Ind Approval And Strong Backing From Key Opinion Leaders, Phase I Clinical Trial Has Commenced, Aimed To Enrol Patients With Solid Tumours. The Project Will Accelerate The Clinical Development Of Ntx1088 Towards A Novel Therapy On The €80 Billion Immune-Oncology Drug Market, Resulting In Better Outcomes For Patients And Reduced Societal And Economic Burden Associated With Cancer.
Funded Under
The European Innovation Council (Eic)
Total Cost
€ 3 571 427,00
Eu Contribution
€ 2 499 998,90
Coordinated By
Nectin Therapeutics Ltd
Israel
Start Date
1 August 2024
End Date
31 January 2028
Objective
Nectin Therapeutics (NectinTx) is a venture-backed company with a top-notch team focused on innovative therapeutic options for cancer patients. To address the limitations of available therapies, the company has developed a diverse pipeline of antibodies that overcome immune inhibitory pathways deployed by the tumours. NTX1088 is a monoclonal antibody that binds human poliovirus receptor (PVR) and activates patient’s immune system to fight cancer through a triple mechanism of action never demonstrated before. A comprehensive preclinical dataset was generated to show the robust antitumor activity of NTX1088 in vitro and in vivo. Following IND approval and strong backing from key opinion leaders, Phase I clinical trial has commenced, aimed to enrol patients with solid tumours. The project will accelerate the clinical development of NTX1088 towards a novel therapy on the €80 billion immune-oncology drug market, resulting in better outcomes for patients and reduced societal and economic burden associated with cancer.
